DRUG 48.00 Bright Minds Biosciences Inc.
| Range: | 0.93-79.02 | Vol Avg: | 2291714 | Last Div: | 0 | Changes: | 25.51 |
| Beta: | 1.73 | Cap: | 0.21B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Mon Mar 22 2021 | Empoloyees: | |||
| CUSIP: | 10919W108 | CIK: | 0001827401 | ISIN: | CA10919W4056 | Country: | CA |
| CEO: | Mr. Ian McDonald | Website: | https://brightmindsbio.com | ||||
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Stock Details
Positive 0.20
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION O...
globenewswire.com·Fri Oct 18 2024
Positive 0.20
Why did this penny stock skyrocket 1,500% in a day
When most major equities recorded notable losses, the share price of biotech company Brigh...
finbold.com·Wed Oct 16 2024
Positive 0.20
Bright Minds Biosciences Stock Surges Almost 1,500%
Bright Minds Biosciences NASDAQ: DRUG, a little-known biotech company, became the talk of ...
marketbeat.com·Wed Oct 16 2024
Positive 0.11
Canadian psychedelics company Bright Minds shares rise 1,446% in one day
Yesterday, Bright Minds Biosciences Inc (CSE:DRUG, OTCQB:BMBIF), a biotech in the field of...
proactiveinvestors.co.uk·Wed Oct 16 2024
Neutral 0.02
Bright Minds is Unaware of Any Material Changes
Vancouver, British Columbia--(Newsfile Corp. - October 15, 2024) - At the request of CIRO,...
newsfilecorp.com·Wed Oct 16 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow